Psilocybin for borderline personality disorder

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 1 Jun 2022: Trial registered, NCT05399498
  2. 1 Nov 2023: Trial started, NCT05399498

The trials

NCT05399498: Psilocybin in Co-occuring Major Depressive Disorder and Borderline Personality Disorder

State
Completed
Phase
Phase 2
People
10 taking part
Started
1 Nov 2023
Primary completion
1 Dec 2025
Arms
Experimental: Psilocybin
Results
Posted on the registry
  1. 1 Jun 2022: Trial registered
  2. 1 Nov 2023: Trial started
  3. 1 Dec 2025: Trial completed
  4. 29 Oct 2026: Trial results posted

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Also known as High Dose Psilocybin, Low Dose Psilocybin, Medium Dose Psilocybin, Psilocybin (0.25mg/kg), Psilocybin (Usona Institute), Psilocybin (drug), Psilocybin 100 mcg/kg, Psilocybin 25 mg, Psilocybin 25 mg per os, Psilocybin 25mg, Psilocybin assisted therapy, Psilocybin first, Psilocybin plus Visual Healing Set and Setting, Psilocybin therapy, psilocybin 25 mg sod.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.